177Lu-PSMA-R2 - Novartis
VISION trial - Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (APCCC 2021) - Dec 14, 2021 - Pres time: Dec 2, 2021; 02:30 PM; No abstract available. 
https://www.prostatecancerconference.org.au/talks/vision-trial-lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer
 
Professor Oliver Sartor, Tulane Medical Centre, United States
 
Dec 14, 2021